Esperion Therapeutics Stock News

Esperion Therapeutics, Inc. (NASDAQ:ESPR) with the stream of -4.20% also noticed, India Galiano Gold Inc. (AMEX:GAU) encountered a rapid change of 1.59% in the last hour of Mondays trading session. The post Beholding Stock: Esperion Therapeutics, Inc. (NASDAQ:ESPR), Galiano Gold Inc. (AMEX:GAU) appeared first on Stocks Equity .

Esperion Therapeutics Inc. ( ESPR , Financial) calls itself the "Lipid Management Company," a pharmaceutical company focused on developing and commercializing affordable, oral, once-daily, non-statin

NEXLETOL and NEXLIZET, treatments for "bad" cholesterol, have high untapped market potential in the US.

Esperion Therapeutics continues to report lackluster growth with their NEXLETOL and NEXLIZET products. As a result, the share price continues to hit fresh all-time-lows with little-to-no signs of a re

Gainers: Bed Bath & Beyond BBBY +6%, Orphazyme (ORPH) +4%, Esperion Therapeutics ESPR +4%, Aurora Innovation (AUROW) +4%, Canadian Solar (CSIQ) +3%. Losers: Gogo

Esperion Therapeutics Inc. (ESPR) shares closed this week 22.4% lower than it did at the end of last week. The stock is currently down 19.4% year-to-date, down 87.0% over the past 12 months, and down 70.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $5.28 and as low as $3.90 this week.Shares closed 89.8% below its 52-week high and 3.3% above its 52-week low.Trading volume this week was 1.3% higher than the 10-day average and 13.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 112.0% The company's stock price performance over the past 12 months lags the peer average by 1022.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Esperion Therapeutics Inc. (ESPR) shares closed today at 0.5% above its 52 week low of $4.13, giving the company a market cap of $120M. The stock is currently down 17.0% year-to-date, down 86.6% over the past 12 months, and down 69.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 29.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 11.5% lower than its 5-day moving average, 17.0% lower than its 20-day moving average, and 52.8% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 164.6% The company's stock price performance over the past 12 months lags the peer average by 1594.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Esperion Therapeutics Inc. (ESPR) shares closed today at 1.4% above its 52 week low of $4.85, giving the company a market cap of $143M. The stock is currently down 81.1% year-to-date, down 82.3% over the past 12 months, and down 60.7% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 56.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1285.8% The company's stock price performance over the past 12 months lags the peer average by -2295.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street analysts forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will report earnings per share of ($2.74) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Esperion Therapeutics earnings, with the highest EPS estimate coming in at ($2.33) and the lowest estimate coming in at ($3.06). Esperion Therapeutics posted earnings per []

Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 0.85 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $317.65M, closed the last trade at $5.16 per share which meant it lost -$0.03 on the day or -0.58% during that session. The ESPR stock price is -665.31% Esperion Therapeutics Inc. (ESPR) Is Down -0.58%, As Bears Mark A Loss Read More »

Esperion Therapeutics Inc. (NASDAQ:ESPR) shares, rose in value on Wednesday, 12/15/21, with the stock price up by 6.57% to the previous days close as strong demand from buyers drove the stock to $5.35. Actively observing the price movement in the last trading, the stock closed the session at $5.02, falling within a range of $4.85 Understanding Esperion Therapeutics Inc. (NASDAQ: ESPR)s Growth Potential Read More »

Esperion Therapeutics, Inc. (NASDAQ:ESPR) saw unusually large options trading on Friday. Traders acquired 3,964 call options on the stock. This represents an increase of approximately 446% compared to the average daily volume of 726 call options. Large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new []

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has earned an average recommendation of Hold from the eleven research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to []

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have received an average recommendation of Hold from the eleven ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, two have given a buy rating and one has assigned a strong []